Join NETRF’s ‘Research Changes Lives’ Giving Tuesday Campaign—Every gift doubled now through December 3, 2024. LEARN MORE
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The results of a phase 2 clinical trial, the Natalie Trial, suggest that the drug cabozantinib may hold promise as a therapeutic option for some
The U.S. Food and Drug Administration approved Lutathera® as the first therapy specifically for patients 12 to 17 years of age who have somatostatin receptor-positive
Carrie Camino joined the NETRF Board of Directors in April of 2024. Carrie is a retired business consultant and partner with West Monroe Partners, where
One of the main challenges in neuroendocrine tumor (NET) research is the scarcity of models that accurately represent the disease. These models are essential for
NETRF-funded researchers have recently reported in the journal GigaScience the first multi-omic dataset of patient-derived tumor organoids of neuroendocrine neoplasms (NENs). This includes large cell
At NETRF, our mission is to fund research that holds promise for advancing the understanding and treatment of neuroendocrine neoplasms (NENs). This is a commitment
Recent advancements have broadened the spectrum of treatments for advanced NETs, encompassing a range of therapies that include peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE.
Four NETRF-funded researchers were recognized for excellence and received awards at the recent European Neuroendocrine Tumor Society (ENETS) annual meeting in Vienna, Austria. CEO Elyse
The FDA has granted breakthrough therapy designation to AlphaMedixTM (212Pb-DOTAMTATE) for treating adults with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), marking it as the first targeted
“Kath Bowl” is an annual event organized by Katherine Mueller’s husband, Matt. “We hold this event every year to celebrate Katherine’s heavenly birthday,” said Matt.
